However, plasma NfL seems to be a promising marker that can indicate pathological changes at early stages in disease development, and therefore, although not specific for AD, it could potentially be considered as a biomarker for the screening of related neurodegeneration and disease prognosis, monitoring and assessment [68–71]. Here, NEFL is linked to Alzheimer disease.